IMNM
Immunome Inc.
$24.39
+0.49 (+2.05%)
At close · Jul 7
Market Cap
$2.80B
Shares
113,250,394
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.39
Open$24.00
Day$23.14–25.00
52W$7.96–27.65
Avg vol 30d1.5M
Short int18.1M · 16.0% float · 12.9d
Short vol66%
Last earningsMay 12, 2026
DataOct 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+16%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
83%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+31%
trailing
6-month return
+19%
trailing
YTD return
+14%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $21 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
1 of 200 funds reported for Jun 30 · net +90 sh shares
Insider flow
Accumulating
Net +$103.9K over 90 days · 50% sells
Short interest
Rising
16.03% of float · ▲ +7.6% MoM · 12.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
−23%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-200.6M
Balance sheet
$653.0M
net cash
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
83%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $21 › 200d $20 — 50d above 200d
Institutional flow
Accumulating
1 of 200 funds reported for Jun 30 · net +90 sh shares
Insider flow
Accumulating
Net +$103.9K over 90 days · 50% sells
Short interest
Rising
16.03% of float · ▲ +7.6% MoM · 12.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $24 · 83%
52-wk high $28
vs 200-day avg +22%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMNM
this stock
Immunome Inc.
|
$2.80B | +13.5% | -23.2% | — | 16.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMNM | +21.9% | +31.3% | +18.6% | +15.1% | +13.6% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +21.0% | +29.9% | +11.0% | +15.0% | +3.9% |